ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
63.293,74
-0,94%
Brent Oil
82,765
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Caladrius Biosciences Inc (CLBS)

  7. Caladrius Biosciences Inc (CLBS) Notícias

CLBS

Caladrius Biosciences (CLBS)

Caladrius Biosciences Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CLBS
DataHoraFonteTítuloCódigoCompanhia
09/05/202317:11Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CLBSCaladrius Biosciences Inc
09/05/202317:09Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CLBSCaladrius Biosciences Inc
30/03/202317:17Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CLBSCaladrius Biosciences Inc
17/01/202319:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CLBSCaladrius Biosciences Inc
17/10/202217:03Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CLBSCaladrius Biosciences Inc
14/10/202217:02Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:CLBSCaladrius Biosciences Inc
16/09/202217:52Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CLBSCaladrius Biosciences Inc
15/09/202210:15GlobeNewswire Inc.Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsNASDAQ:CLBSCaladrius Biosciences Inc
14/09/202209:00GlobeNewswire Inc.Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsNASDAQ:CLBSCaladrius Biosciences Inc
12/09/202209:35GlobeNewswire Inc.Life Sciences Virtual Investor Conference Agenda Announced for September 15thNASDAQ:CLBSCaladrius Biosciences Inc
08/09/202209:00GlobeNewswire Inc.Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022NASDAQ:CLBSCaladrius Biosciences Inc
15/08/202207:57Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:CLBSCaladrius Biosciences Inc
10/08/202212:40TipRanksAnalysts Conflicted on These Healthcare Names: Haemonetics (HAE), Caladrius Biosciences (CLBS) and Adicet Bio (ACET)NASDAQ:CLBSCaladrius Biosciences Inc
10/08/202209:00GlobeNewswire Inc.Caladrius Biosciences’ Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic CancerNASDAQ:CLBSCaladrius Biosciences Inc
07/08/202209:25TipRanksDawson James Sticks to Its Hold Rating for Caladrius Biosciences (CLBS)NASDAQ:CLBSCaladrius Biosciences Inc
05/08/202207:26TipRanksH.C. Wainwright Thinks Caladrius Biosciences’ Stock is Going to RecoverNASDAQ:CLBSCaladrius Biosciences Inc
04/08/202217:05GlobeNewswire Inc.Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:CLBSCaladrius Biosciences Inc
02/08/202209:00GlobeNewswire Inc.Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney DiseaseNASDAQ:CLBSCaladrius Biosciences Inc
29/07/202217:07Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:CLBSCaladrius Biosciences Inc
28/07/202209:00GlobeNewswire Inc.Caladrius Biosciences to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 4, 2022, at 4:30 p.m. Eastern TimeNASDAQ:CLBSCaladrius Biosciences Inc
06/07/202209:00GlobeNewswire Inc.Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and HepatologyNASDAQ:CLBSCaladrius Biosciences Inc
09/06/202209:00GlobeNewswire Inc.Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials GroupNASDAQ:CLBSCaladrius Biosciences Inc
08/06/202209:00GlobeNewswire Inc.Caladrius Biosciences to Present at the BIO International Convention 2022NASDAQ:CLBSCaladrius Biosciences Inc
26/05/202209:00GlobeNewswire Inc.Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual MeetingNASDAQ:CLBSCaladrius Biosciences Inc
24/05/202211:15TipRanksCaladrius Biosciences (CLBS) Gets a Buy Rating from Brookline Capital MarketsNASDAQ:CLBSCaladrius Biosciences Inc
24/05/202210:15TipRanksAnalysts Offer Insights on Healthcare Companies: Caladrius Biosciences (CLBS) and Alzamend Neuro (ALZN)NASDAQ:CLBSCaladrius Biosciences Inc
23/05/202217:05GlobeNewswire Inc.Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular DysfunctionNASDAQ:CLBSCaladrius Biosciences Inc
19/05/202209:00GlobeNewswire Inc.Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney DiseaseNASDAQ:CLBSCaladrius Biosciences Inc
18/05/202209:00GlobeNewswire Inc.Caladrius Biosciences to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:CLBSCaladrius Biosciences Inc
09/05/202203:16TipRanksBrookline Capital Markets Thinks Caladrius Biosciences’ Stock is Going to RecoverNASDAQ:CLBSCaladrius Biosciences Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CLBS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZUL4
AZUL PN
BOV
GOLL4
GOL PN
BOV
HETA4
HERCULES PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados